AKT1 and type 2 diabetes mellitus: It is notable is that long-term treatment with RAPA blocks mTORC2-mediated Akt phosphorylation/activation; therefore the use of RAPA for the treatment type 2 diabetes can be a clinical challenge (Sarbassov et al., 2005).